,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aJ2AS'}, 'Id': 'a0POZ000000R9aJ2AS', 'Event_Date__c': '2022-08-08', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000DyChQAK'}, 'change': None}]",Aug 2022,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aL2AS'}, 'Id': 'a0POZ000000R9aL2AS', 'Event_Date__c': '2022-12-07', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000ED7ZQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'fs': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aP2AS'}, 'Id': 'a0POZ000000R9aP2AS', 'Event_Date__c': '2023-02-28', 'Event_Description__c': 'Assigned to Rare Disorders Advisory Committee meeting to provide advice on Tuesday 7 March 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDcSQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory</span> Committees <strong>recommended</strong> that risdiplam for the pre-symptomatic treatment of SMA be listed with a <strong>high priority</strong> within the context of treatments for rare disorders, subject to the following Special Authority criteria (changes to current proposed criteria marked in bold):</p><p class=""ql-indent-1""><strong style=""color: rgb(51, 51, 51); font-family: Arial, sans-serif; font-size: 9pt;"">Initial application –\xa0(spinal muscular atrophy (SMA))</strong><span style=""color: rgb(51, 51, 51); font-family: Arial, sans-serif; font-size: 9pt;"">\xa0from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">1.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has genetic documentation of\xa0homozygous\xa0SMN1\xa0gene deletion, homozygous\xa0SMN1 point\xa0mutation, or compound heterozygous mutation; and</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">2.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient is 18 years of age or under; and</span></p><p class=""ql-indent-2""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Either:</strong></p><p class=""ql-indent-3""><span style=""color: black; font-size: 9pt;"">3.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or</span></p><p class=""ql-indent-3""><span style=""color: black; font-size: 9pt;"">3.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Both:</strong></p><p class=""ql-indent-4""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.2.1.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient is pre-symptomatic; and</strong></p><p class=""ql-indent-4""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.2.2.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has\xa0three or less copies of SMN2\xa0</strong></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Renewal –\xa0(spinal muscular atrophy (SMA)</strong><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">\xa0from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Both of the following</span><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">:</strong></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">1.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function\xa0since treatment initiation; and</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">2.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient does not require invasive permanent ventilation (</span><strike style=""color: rgb(51, 51, 51); font-size: 9pt;"">≥\xa0</strike><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">at least\xa016 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy</span></p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In <span style=""color: black;"">making</span> this recommendation the Committees considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That individuals with pre-symptomatic SMA had the greatest potential to benefit from treatment with risdiplam;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That it is currently considered that both risdiplam and nusinersen have similar clinical effects on SMA;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That there are individuals diagnosed with pre-symptomatic SMA for whom treatment with nusinersen is unsuitable. This may include those who live in rural areas where access to institutional treatment with nusinersen may be a barrier to treatment access;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That risdiplam has suitability advantages over nusinersen as it is an oral, at home treatment rather than an intrathecal treatment.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory</span> Committees <strong>recommended</strong> that risdiplam for the pre-symptomatic treatment of SMA be listed with a <strong>high priority</strong> within the context of treatments for rare disorders, subject to the following Special Authority criteria (changes to current proposed criteria marked in bold):</p><p class=""ql-indent-1""><strong style=""color: rgb(51, 51, 51); font-family: Arial, sans-serif; font-size: 9pt;"">Initial application –\xa0(spinal muscular atrophy (SMA))</strong><span style=""color: rgb(51, 51, 51); font-family: Arial, sans-serif; font-size: 9pt;"">\xa0from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">1.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has genetic documentation of\xa0homozygous\xa0SMN1\xa0gene deletion, homozygous\xa0SMN1 point\xa0mutation, or compound heterozygous mutation; and</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">2.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient is 18 years of age or under; and</span></p><p class=""ql-indent-2""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Either:</strong></p><p class=""ql-indent-3""><span style=""color: black; font-size: 9pt;"">3.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or</span></p><p class=""ql-indent-3""><span style=""color: black; font-size: 9pt;"">3.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Both:</strong></p><p class=""ql-indent-4""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.2.1.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient is pre-symptomatic; and</strong></p><p class=""ql-indent-4""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.2.2.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has\xa0three or less copies of SMN2\xa0</strong></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Renewal –\xa0(spinal muscular atrophy (SMA)</strong><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">\xa0from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Both of the following</span><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">:</strong></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">1.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function\xa0since treatment initiation; and</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">2.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient does not require invasive permanent ventilation (</span><strike style=""color: rgb(51, 51, 51); font-size: 9pt;"">≥\xa0</strike><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">at least\xa016 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy</span></p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In <span style=""color: black;"">making</span> this recommendation the Committees considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That individuals with pre-symptomatic SMA had the greatest potential to benefit from treatment with risdiplam;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That it is currently considered that both risdiplam and nusinersen have similar clinical effects on SMA;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That there are individuals diagnosed with pre-symptomatic SMA for whom treatment with nusinersen is unsuitable. This may include those who live in rural areas where access to institutional treatment with nusinersen may be a barrier to treatment access;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That risdiplam has suitability advantages over nusinersen as it is an oral, at home treatment rather than an intrathecal treatment.</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees discussed the impact of funding risdiplam for the treatment of pre-symptomatic SMA on Māori health areas of focus and Māori health outcomes. The Committees noted the lower reported prevalence and incidence of SMA in Māori, and considered the presence of a mutation in the <em>SMN1</em> gene does not appear to be associated with or influenced by ethnicity. However, the Committee considered that there is inequitable access to obstetric and early postnatal care, as well as a lack of health literacy and support from culturally appropriate health care workers that could impact on Māori access to newborn screening, resulting in lower access to screening, and consequently lower access to more efficacious pre-symptomatic treatment. The Committees noted that SMA is not included as a Māori health area of focus in Te Whaioranga, Pharmac’s Māori responsiveness strategy.</p><h3><em style=""font-size: 14px;"">Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that in <a href=""https://pharmac.govt.nz/assets/ptac-rare-disorder-subcommittee-record-2019-09.pdf"" target=""_blank"">September 2019</a>, the Rare Disorders Subcommittee (now Specialist Advisory Committee) recommended nusinersen be funded with a high priority for the treatment of pre-symptomatic SMA in individuals with two or three SMN2 copies, subject to special authority criteria. The Committees noted that this recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, longer-term evidence of survival gain and meaningful clinical benefit with nusinersen, and that individuals with pre-symptomatic SMA had the greatest potential to benefit from treatment.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that from 1 January 2023, nusinersen has been funded for pre-symptomatic SMA (as well as SMA types I, II, or IIIa).</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that in <a href=""https://pharmac.govt.nz/assets/2021-03-05-Record-of-the-Rare-Disorders-and-Neurological-Subcommittee-meeting-record.pdf"" target=""_blank"">March 2021</a>, the Rare Disorders and Neurological Subcommittees recommended that risdiplam for the treatment of type I SMA be listed with a high priority and deferred a recommendation for the funding of risdiplam for types II and III. The Committees noted that in August 2021 PTAC recommended that risdiplam for the treatment of type I spinal muscular atrophy be listed with a high priority and recommended that risdiplam for the treatment of types II and IIIa spinal muscular atrophy (aged 18 years and under) be listed with a medium priority. In <a href=""https://pharmac.govt.nz/assets/2021-07-06-Rare-Disorders-and-Neurological-Subcommittees-meeting.pdf"" target=""_blank"">July 2021</a> the Rare Disorders and Neurological Subcommittees recommended that risdiplam for the treatment of types II and III SMA (in individuals aged under 25 years) with a high priority, following the review of further evidence.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that at the time of the meeting, Pharmac was reviewing consultation feedback on a proposal to fund risdiplam from 1 May 2023 for the treatment of SMA types I, II, and IIIa for people who start treatment when they’re 18 years old and younger.</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that the health need of people with pre-symptomatic SMA has been considered in previous clinical advice<a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009QXCv/p001488"" target=""_blank""> meetings</a>. The Committees re-iterated that pre-symptomatic individuals are likely to gain the greatest benefits from SMA treatment, due to minimising the number of motor neurones lost and associated level of lost physical functionality</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that individuals who are pre-symptomatic are unable to be classified as type I, II, III or IV, which are defined based on time of symptom onset; and so are classified by the number of SMN2 copies, due to current evidence indicating that number of SMN2 copies correlating inversely with disease severity.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees considered that approximately 90% of SMA cases are able to be diagnosed by local testing of exon 7 deletion of chromosome 5q, and that this estimation as calculated is in line with <a href=""http://www.msac.gov.au/internet/msac/publishing.nsf/Content/552F338BE4BEBA0FCA2583D000051738/$File/1589%20-%20Final%20PSD.pdf"" target=""_blank"">MSAC calculations in Australia. </a>\xa0The Committees noted that in cases with negative test results but high clinical suspicion, the more accurate <em>SMN1</em> gene sequencing test can be requested from the Victorian Clinical Genetic Service in Australia. The Committees noted the specificity of local genetic testing (near 100%) and high sensitivity (90% x 85% = 76.5%).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that approximately 85% of people with SMA types I, II or III had less than or equal to 3 <em>SMN2</em> copies, in a study of 272 patients <a href=""https://www.sciencedirect.com/science/article/abs/pii/S096089661730490X?via%3Dihub"" target=""_blank"">(Calucho et al. Neuromuscular Disorders. 2018;28(3):208-15)</a>, meaning that approximately four people per year would be expected to be diagnosed pre-symptomatically with a threshold of three SMN2 copies. The Committees noted the distribution of <em>SMN2</em> copy numbers according to SMA type in Calucho et al. – of 625 participants with SMA, 8.15% of participants with SMA Type III had four copies of <em>SMN2</em>. All other participants with Type 3 SMA, as well as all participants with Types 1 and 2 SMA, had 3 or less copies of <em>SMN2</em>.\xa0</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that if the proposed funding criteria for risdiplam limits the number of <em>SMN2</em> copies to 3 as per the current nusinersen funding criteria, then some individuals with Type 3 SMA may be missed at the time of screening. Members considered that the proposed funding criteria increased the limit number of <em>SMN2</em> copies to 4, then some individuals would be treated pre-symptomatically – who otherwise would manifest SMA type IIIb or IV (who would not otherwise be eligible for treatment), or may never become symptomatic.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that based on previous consideration by PTAC and the Rare Disorders and Neurological Subcommittees, a large proportion of people with SMA would be assumed to have an SMA type IV phenotype if treated in the pre-symptomatic setting. The Committees considered it important that the morbidity associated with an SMA type IV phenotype be reflected in economic modelling in the decades after symptom onset with this phenotype, given the recommended assumption of lifelong benefit.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees discussed the impact of funding risdiplam for the treatment of pre-symptomatic SMA on Māori health areas of focus and Māori health outcomes. The Committees noted the lower reported prevalence and incidence of SMA in Māori, and considered the presence of a mutation in the <em>SMN1 </em>gene does not appear to be associated with or influenced by ethnicity. The Committees noted that SMA is not included as a Māori health area of focus in Te Whaioranga, Pharmac Māori responsiveness strategy.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that routine screen of all newborns for SMA is not currently routinely available in New Zealand; however, that following the funding of nusinersen, this may be developed. The Committees noted that access to and utilisation of screening would not be changed with the addition of risdiplam as a treatment option in the pre-symptomatic setting.</p><h3><em style=""font-size: 14px;"">Health Benefit</em></h3><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that Medsafe has approved the use of risdiplam in people aged two months and over and that further assessment is currently underway to extend the indication to remove the age restriction. The Committees noted that all infants included in the RAINBOWFISH study were under two months old, and that the youngest started treatment at 28.5 days old.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted the 12-month interim results of the RAINBOWFISH trial, an open label study of infants with genetically diagnosed and pre-symptomatic SMA (<a href=""https://medically.gene.com/global/en/unrestricted/neuroscience/CURE-SMA-2022/curesma-2022-presentation-richard-rainbowfish-prelimina.html"" target=""_blank"">Finkel et al. Cure SMA 2022 presentation on behalf of the RAINBOWFISH study group, sponsored by Roche. Anaheim, USA; 2022 June 16).\xa0</a></p><p class=""ql-indent-1"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that at the cut-off for interim data, seven infants had been treated with risdiplam for 12 months or more. Four infants had two <em>SMN2</em> copies, and three had &gt;2 <em>SMN2</em> copies (number of copies not further defined). The Committees noted the mean HINE-2 score change from baseline was 18.75. All infants were sitting without support, six patients achieved the highest levels of rolling (supine to prone), and five infants were walking independently. All included infants maintained the ability to swallow and were able to feed exclusively by mouth.</p><p class=""ql-indent-1"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted the investigator’s report concluded that adverse events (AEs) were more reflective of the age of the infants rather than the underlying SMA, or treatment with risdiplam. The Committees noted that at 12 months no deaths, no serious AEs, or AEs that led to treatment withdrawal or discontinuation were reported. Members noted that unlike nusinersen, which is administered as an intrathecal injection, risdiplam does not carry the risks associated with intrathecal injection and sedation.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that there are currently no direct head-to-head trials of nusinersen and risdiplam in the pre-symptomatic setting. The Committees considered that while patient numbers in trials for each medicine are relatively small, which makes them difficult to compare, it is currently considered that both risdiplam and nusinersen have similar clinical effects on SMA. Members considered, that based on the similar mechanisms of action, this was biologically plausible.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that once new-born screening for SMA was in place, most individuals would be diagnosed and begin treatment pre-symptomatically. Members considered that this would provide additional treatment benefit in comparison to treatment initiation after the onset of symptoms.</p><h3><em style=""font-size: 14px;"">Suitability</em></h3><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that risdiplam is a once daily oral medication, presented as a powder for reconstitution with purified or sterile water which is to be reconstituted by a healthcare professional. The Committees noted that risdiplam can also be given via nasogastric tube, or gastrostomy.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that not being required to travel to hospital for intrathecal treatment (as with nusinersen) was a clear suitability benefit for risdiplam, particularly for individuals who live in rural areas and may find accessing clinical centres for nusinersen treatment difficult.</p><h3><em style=""font-size: 14px;"">Cost and savings</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that eventually 90% of those with pre-symptomatic SMA would initiate treatment with risdiplam preferentially to treatment with nusinersen, due to the suitability of oral treatment compared with repeated intrathecal injections. The Committees noted that this was supported by a recent discrete choice experiment conducted with patients and caregivers of patients with SMA <a href=""https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01667-3"" target=""_blank"">(Monnette et al. Orphanet J Rare Dis. 2021;16:36</a>).</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that there would be a cost associated with implementing a national screening service for SMA, but that this cost would be incurred regardless of the funding of risdiplam, as nusinersen has been funded for this indication already.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that, compared with nusinersen intrathecal injection treatment for SMA, oral risdiplam has the potential to reduce health system costs to a greater extent, with the same or similar efficacy likely to be achieved.</p><h3><em style=""font-size: 14px;"">Summary for assessment</em></h3><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committees considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) </span>information<span style=""color: black;""> for risdiplam if it were to be funded in New Zealand for </span>pre-symptomatic treatment of SMA<span style=""color: black;"">. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committees’ assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Committees noted that the PICO table below was relevant for all individuals with SMA not just those who will be diagnosed pre-symptomatically. The Committees also noted that the intervention would commence when individuals were less than 2 months old.\xa0</span></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000000R9aR&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005Q0H"" alt=""image.png""></img></p>', 'fs': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees discussed the impact of funding risdiplam for the treatment of pre-symptomatic SMA on Māori health areas of focus and Māori health outcomes. The Committees noted the lower reported prevalence and incidence of SMA in Māori, and considered the presence of a mutation in the <em>SMN1</em> gene does not appear to be associated with or influenced by ethnicity. However, the Committee considered that there is inequitable access to obstetric and early postnatal care, as well as a lack of health literacy and support from culturally appropriate health care workers that could impact on Māori access to newborn screening, resulting in lower access to screening, and consequently lower access to more efficacious pre-symptomatic treatment. The Committees noted that SMA is not included as a Māori health area of focus in Te Whaioranga, Pharmac’s Māori responsiveness strategy.</p><h3><em style=""font-size: 14px;"">Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that in <a href=""https://pharmac.govt.nz/assets/ptac-rare-disorder-subcommittee-record-2019-09.pdf"" target=""_blank"">September 2019</a>, the Rare Disorders Subcommittee (now Specialist Advisory Committee) recommended nusinersen be funded with a high priority for the treatment of pre-symptomatic SMA in individuals with two or three SMN2 copies, subject to special authority criteria. The Committees noted that this recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, longer-term evidence of survival gain and meaningful clinical benefit with nusinersen, and that individuals with pre-symptomatic SMA had the greatest potential to benefit from treatment.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that from 1 January 2023, nusinersen has been funded for pre-symptomatic SMA (as well as SMA types I, II, or IIIa).</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that in <a href=""https://pharmac.govt.nz/assets/2021-03-05-Record-of-the-Rare-Disorders-and-Neurological-Subcommittee-meeting-record.pdf"" target=""_blank"">March 2021</a>, the Rare Disorders and Neurological Subcommittees recommended that risdiplam for the treatment of type I SMA be listed with a high priority and deferred a recommendation for the funding of risdiplam for types II and III. The Committees noted that in August 2021 PTAC recommended that risdiplam for the treatment of type I spinal muscular atrophy be listed with a high priority and recommended that risdiplam for the treatment of types II and IIIa spinal muscular atrophy (aged 18 years and under) be listed with a medium priority. In <a href=""https://pharmac.govt.nz/assets/2021-07-06-Rare-Disorders-and-Neurological-Subcommittees-meeting.pdf"" target=""_blank"">July 2021</a> the Rare Disorders and Neurological Subcommittees recommended that risdiplam for the treatment of types II and III SMA (in individuals aged under 25 years) with a high priority, following the review of further evidence.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that at the time of the meeting, Pharmac was reviewing consultation feedback on a proposal to fund risdiplam from 1 May 2023 for the treatment of SMA types I, II, and IIIa for people who start treatment when they’re 18 years old and younger.</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that the health need of people with pre-symptomatic SMA has been considered in previous clinical advice<a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009QXCv/p001488"" target=""_blank""> meetings</a>. The Committees re-iterated that pre-symptomatic individuals are likely to gain the greatest benefits from SMA treatment, due to minimising the number of motor neurones lost and associated level of lost physical functionality</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that individuals who are pre-symptomatic are unable to be classified as type I, II, III or IV, which are defined based on time of symptom onset; and so are classified by the number of SMN2 copies, due to current evidence indicating that number of SMN2 copies correlating inversely with disease severity.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees considered that approximately 90% of SMA cases are able to be diagnosed by local testing of exon 7 deletion of chromosome 5q, and that this estimation as calculated is in line with <a href=""http://www.msac.gov.au/internet/msac/publishing.nsf/Content/552F338BE4BEBA0FCA2583D000051738/$File/1589%20-%20Final%20PSD.pdf"" target=""_blank"">MSAC calculations in Australia. </a>\xa0The Committees noted that in cases with negative test results but high clinical suspicion, the more accurate <em>SMN1</em> gene sequencing test can be requested from the Victorian Clinical Genetic Service in Australia. The Committees noted the specificity of local genetic testing (near 100%) and high sensitivity (90% x 85% = 76.5%).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that approximately 85% of people with SMA types I, II or III had less than or equal to 3 <em>SMN2</em> copies, in a study of 272 patients <a href=""https://www.sciencedirect.com/science/article/abs/pii/S096089661730490X?via%3Dihub"" target=""_blank"">(Calucho et al. Neuromuscular Disorders. 2018;28(3):208-15)</a>, meaning that approximately four people per year would be expected to be diagnosed pre-symptomatically with a threshold of three SMN2 copies. The Committees noted the distribution of <em>SMN2</em> copy numbers according to SMA type in Calucho et al. – of 625 participants with SMA, 8.15% of participants with SMA Type III had four copies of <em>SMN2</em>. All other participants with Type 3 SMA, as well as all participants with Types 1 and 2 SMA, had 3 or less copies of <em>SMN2</em>.\xa0</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that if the proposed funding criteria for risdiplam limits the number of <em>SMN2</em> copies to 3 as per the current nusinersen funding criteria, then some individuals with Type 3 SMA may be missed at the time of screening. Members considered that the proposed funding criteria increased the limit number of <em>SMN2</em> copies to 4, then some individuals would be treated pre-symptomatically – who otherwise would manifest SMA type IIIb or IV (who would not otherwise be eligible for treatment), or may never become symptomatic.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that based on previous consideration by PTAC and the Rare Disorders and Neurological Subcommittees, a large proportion of people with SMA would be assumed to have an SMA type IV phenotype if treated in the pre-symptomatic setting. The Committees considered it important that the morbidity associated with an SMA type IV phenotype be reflected in economic modelling in the decades after symptom onset with this phenotype, given the recommended assumption of lifelong benefit.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees discussed the impact of funding risdiplam for the treatment of pre-symptomatic SMA on Māori health areas of focus and Māori health outcomes. The Committees noted the lower reported prevalence and incidence of SMA in Māori, and considered the presence of a mutation in the <em>SMN1 </em>gene does not appear to be associated with or influenced by ethnicity. The Committees noted that SMA is not included as a Māori health area of focus in Te Whaioranga, Pharmac Māori responsiveness strategy.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that routine screen of all newborns for SMA is not currently routinely available in New Zealand; however, that following the funding of nusinersen, this may be developed. The Committees noted that access to and utilisation of screening would not be changed with the addition of risdiplam as a treatment option in the pre-symptomatic setting.</p><h3><em style=""font-size: 14px;"">Health Benefit</em></h3><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that Medsafe has approved the use of risdiplam in people aged two months and over and that further assessment is currently underway to extend the indication to remove the age restriction. The Committees noted that all infants included in the RAINBOWFISH study were under two months old, and that the youngest started treatment at 28.5 days old.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted the 12-month interim results of the RAINBOWFISH trial, an open label study of infants with genetically diagnosed and pre-symptomatic SMA (<a href=""https://medically.gene.com/global/en/unrestricted/neuroscience/CURE-SMA-2022/curesma-2022-presentation-richard-rainbowfish-prelimina.html"" target=""_blank"">Finkel et al. Cure SMA 2022 presentation on behalf of the RAINBOWFISH study group, sponsored by Roche. Anaheim, USA; 2022 June 16).\xa0</a></p><p class=""ql-indent-1"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that at the cut-off for interim data, seven infants had been treated with risdiplam for 12 months or more. Four infants had two <em>SMN2</em> copies, and three had &gt;2 <em>SMN2</em> copies (number of copies not further defined). The Committees noted the mean HINE-2 score change from baseline was 18.75. All infants were sitting without support, six patients achieved the highest levels of rolling (supine to prone), and five infants were walking independently. All included infants maintained the ability to swallow and were able to feed exclusively by mouth.</p><p class=""ql-indent-1"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted the investigator’s report concluded that adverse events (AEs) were more reflective of the age of the infants rather than the underlying SMA, or treatment with risdiplam. The Committees noted that at 12 months no deaths, no serious AEs, or AEs that led to treatment withdrawal or discontinuation were reported. Members noted that unlike nusinersen, which is administered as an intrathecal injection, risdiplam does not carry the risks associated with intrathecal injection and sedation.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that there are currently no direct head-to-head trials of nusinersen and risdiplam in the pre-symptomatic setting. The Committees considered that while patient numbers in trials for each medicine are relatively small, which makes them difficult to compare, it is currently considered that both risdiplam and nusinersen have similar clinical effects on SMA. Members considered, that based on the similar mechanisms of action, this was biologically plausible.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that once new-born screening for SMA was in place, most individuals would be diagnosed and begin treatment pre-symptomatically. Members considered that this would provide additional treatment benefit in comparison to treatment initiation after the onset of symptoms.</p><h3><em style=""font-size: 14px;"">Suitability</em></h3><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that risdiplam is a once daily oral medication, presented as a powder for reconstitution with purified or sterile water which is to be reconstituted by a healthcare professional. The Committees noted that risdiplam can also be given via nasogastric tube, or gastrostomy.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that not being required to travel to hospital for intrathecal treatment (as with nusinersen) was a clear suitability benefit for risdiplam, particularly for individuals who live in rural areas and may find accessing clinical centres for nusinersen treatment difficult.</p><h3><em style=""font-size: 14px;"">Cost and savings</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that eventually 90% of those with pre-symptomatic SMA would initiate treatment with risdiplam preferentially to treatment with nusinersen, due to the suitability of oral treatment compared with repeated intrathecal injections. The Committees noted that this was supported by a recent discrete choice experiment conducted with patients and caregivers of patients with SMA <a href=""https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01667-3"" target=""_blank"">(Monnette et al. Orphanet J Rare Dis. 2021;16:36</a>).</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that there would be a cost associated with implementing a national screening service for SMA, but that this cost would be incurred regardless of the funding of risdiplam, as nusinersen has been funded for this indication already.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that, compared with nusinersen intrathecal injection treatment for SMA, oral risdiplam has the potential to reduce health system costs to a greater extent, with the same or similar efficacy likely to be achieved.</p><h3><em style=""font-size: 14px;"">Summary for assessment</em></h3><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committees considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) </span>information<span style=""color: black;""> for risdiplam if it were to be funded in New Zealand for </span>pre-symptomatic treatment of SMA<span style=""color: black;"">. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committees’ assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Committees noted that the PICO table below was relevant for all individuals with SMA not just those who will be diagnosed pre-symptomatically. The Committees also noted that the intervention would commence when individuals were less than 2 months old.\xa0</span></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000000R9aR&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005Q0H"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory</span> Committees reviewed the application for risdiplam (Evrysdi) for the treatment of pre-symptomatic spinal muscular atrophy (SMA).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees took into account, where applicable, Pharmac’s relevant decision-<span style=""color: black;"">making</span> framework when considering this agenda item.</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory</span> Committees reviewed the application for risdiplam (Evrysdi) for the treatment of pre-symptomatic spinal muscular atrophy (SMA).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees took into account, where applicable, Pharmac’s relevant decision-<span style=""color: black;"">making</span> framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'fs': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aR2AS'}, 'Id': 'a0POZ000000R9aR2AS', 'Event_Date__c': '2023-08-11', 'Event_Description__c': 'Clinical advice received from Rare Disorders Advisory Committee at meeting Tuesday 7 March 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Aug 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory</span> Committees <strong>recommended</strong> that risdiplam for the pre-symptomatic treatment of SMA be listed with a <strong>high priority</strong> within the context of treatments for rare disorders, subject to the following Special Authority criteria (changes to current proposed criteria marked in bold):</p><p class=""ql-indent-1""><strong style=""color: rgb(51, 51, 51); font-family: Arial, sans-serif; font-size: 9pt;"">Initial application –\xa0(spinal muscular atrophy (SMA))</strong><span style=""color: rgb(51, 51, 51); font-family: Arial, sans-serif; font-size: 9pt;"">\xa0from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">1.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has genetic documentation of\xa0homozygous\xa0SMN1\xa0gene deletion, homozygous\xa0SMN1 point\xa0mutation, or compound heterozygous mutation; and</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">2.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient is 18 years of age or under; and</span></p><p class=""ql-indent-2""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Either:</strong></p><p class=""ql-indent-3""><span style=""color: black; font-size: 9pt;"">3.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has experienced the defined signs and symptoms of SMA type I, II or IIIa prior to three years of age; or</span></p><p class=""ql-indent-3""><span style=""color: black; font-size: 9pt;"">3.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0</span><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Both:</strong></p><p class=""ql-indent-4""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.2.1.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient is pre-symptomatic; and</strong></p><p class=""ql-indent-4""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.2.2.</strong><strong style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</strong><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient has\xa0three or less copies of SMN2\xa0</strong></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">Renewal –\xa0(spinal muscular atrophy (SMA)</strong><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">\xa0from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Both of the following</span><strong style=""color: rgb(51, 51, 51); font-size: 9pt;"">:</strong></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">1.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">There has been demonstrated maintenance of motor milestone function\xa0since treatment initiation; and</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">2.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Patient does not require invasive permanent ventilation (</span><strike style=""color: rgb(51, 51, 51); font-size: 9pt;"">≥\xa0</strike><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">at least\xa016 hours per day) in the absence of a potentially reversible cause while being treated with risdiplam</span></p><p class=""ql-indent-2""><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">3.</span><span style=""color: rgb(51, 51, 51); font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""color: rgb(51, 51, 51); font-size: 9pt;"">Risdiplam not to be administered in combination other SMA disease modifying treatments or gene therapy</span></p><p><br></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>In <span style=""color: black;"">making</span> this recommendation the Committees considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That individuals with pre-symptomatic SMA had the greatest potential to benefit from treatment with risdiplam;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That it is currently considered that both risdiplam and nusinersen have similar clinical effects on SMA;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That there are individuals diagnosed with pre-symptomatic SMA for whom treatment with nusinersen is unsuitable. This may include those who live in rural areas where access to institutional treatment with nusinersen may be a barrier to treatment access;</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That risdiplam has suitability advantages over nusinersen as it is an oral, at home treatment rather than an intrathecal treatment.</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory</span> Committees reviewed the application for risdiplam (Evrysdi) for the treatment of pre-symptomatic spinal muscular atrophy (SMA).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committees took into account, where applicable, Pharmac’s relevant decision-<span style=""color: black;"">making</span> framework when considering this agenda item.</p>', 'Published_Discussion__c': '<h3><em style=""font-size: 14px;"">Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees discussed the impact of funding risdiplam for the treatment of pre-symptomatic SMA on Māori health areas of focus and Māori health outcomes. The Committees noted the lower reported prevalence and incidence of SMA in Māori, and considered the presence of a mutation in the <em>SMN1</em> gene does not appear to be associated with or influenced by ethnicity. However, the Committee considered that there is inequitable access to obstetric and early postnatal care, as well as a lack of health literacy and support from culturally appropriate health care workers that could impact on Māori access to newborn screening, resulting in lower access to screening, and consequently lower access to more efficacious pre-symptomatic treatment. The Committees noted that SMA is not included as a Māori health area of focus in Te Whaioranga, Pharmac’s Māori responsiveness strategy.</p><h3><em style=""font-size: 14px;"">Background</em></h3><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that in <a href=""https://pharmac.govt.nz/assets/ptac-rare-disorder-subcommittee-record-2019-09.pdf"" target=""_blank"">September 2019</a>, the Rare Disorders Subcommittee (now Specialist Advisory Committee) recommended nusinersen be funded with a high priority for the treatment of pre-symptomatic SMA in individuals with two or three SMN2 copies, subject to special authority criteria. The Committees noted that this recommendation was based on the absence of funded alternatives, the high health need of these individuals and their family/whānau, longer-term evidence of survival gain and meaningful clinical benefit with nusinersen, and that individuals with pre-symptomatic SMA had the greatest potential to benefit from treatment.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that from 1 January 2023, nusinersen has been funded for pre-symptomatic SMA (as well as SMA types I, II, or IIIa).</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that in <a href=""https://pharmac.govt.nz/assets/2021-03-05-Record-of-the-Rare-Disorders-and-Neurological-Subcommittee-meeting-record.pdf"" target=""_blank"">March 2021</a>, the Rare Disorders and Neurological Subcommittees recommended that risdiplam for the treatment of type I SMA be listed with a high priority and deferred a recommendation for the funding of risdiplam for types II and III. The Committees noted that in August 2021 PTAC recommended that risdiplam for the treatment of type I spinal muscular atrophy be listed with a high priority and recommended that risdiplam for the treatment of types II and IIIa spinal muscular atrophy (aged 18 years and under) be listed with a medium priority. In <a href=""https://pharmac.govt.nz/assets/2021-07-06-Rare-Disorders-and-Neurological-Subcommittees-meeting.pdf"" target=""_blank"">July 2021</a> the Rare Disorders and Neurological Subcommittees recommended that risdiplam for the treatment of types II and III SMA (in individuals aged under 25 years) with a high priority, following the review of further evidence.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that at the time of the meeting, Pharmac was reviewing consultation feedback on a proposal to fund risdiplam from 1 May 2023 for the treatment of SMA types I, II, and IIIa for people who start treatment when they’re 18 years old and younger.</p><h3><em style=""font-size: 14px;"">Health need</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that the health need of people with pre-symptomatic SMA has been considered in previous clinical advice<a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000009QXCv/p001488"" target=""_blank""> meetings</a>. The Committees re-iterated that pre-symptomatic individuals are likely to gain the greatest benefits from SMA treatment, due to minimising the number of motor neurones lost and associated level of lost physical functionality</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that individuals who are pre-symptomatic are unable to be classified as type I, II, III or IV, which are defined based on time of symptom onset; and so are classified by the number of SMN2 copies, due to current evidence indicating that number of SMN2 copies correlating inversely with disease severity.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees considered that approximately 90% of SMA cases are able to be diagnosed by local testing of exon 7 deletion of chromosome 5q, and that this estimation as calculated is in line with <a href=""http://www.msac.gov.au/internet/msac/publishing.nsf/Content/552F338BE4BEBA0FCA2583D000051738/$File/1589%20-%20Final%20PSD.pdf"" target=""_blank"">MSAC calculations in Australia. </a>\xa0The Committees noted that in cases with negative test results but high clinical suspicion, the more accurate <em>SMN1</em> gene sequencing test can be requested from the Victorian Clinical Genetic Service in Australia. The Committees noted the specificity of local genetic testing (near 100%) and high sensitivity (90% x 85% = 76.5%).</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committees noted that approximately 85% of people with SMA types I, II or III had less than or equal to 3 <em>SMN2</em> copies, in a study of 272 patients <a href=""https://www.sciencedirect.com/science/article/abs/pii/S096089661730490X?via%3Dihub"" target=""_blank"">(Calucho et al. Neuromuscular Disorders. 2018;28(3):208-15)</a>, meaning that approximately four people per year would be expected to be diagnosed pre-symptomatically with a threshold of three SMN2 copies. The Committees noted the distribution of <em>SMN2</em> copy numbers according to SMA type in Calucho et al. – of 625 participants with SMA, 8.15% of participants with SMA Type III had four copies of <em>SMN2</em>. All other participants with Type 3 SMA, as well as all participants with Types 1 and 2 SMA, had 3 or less copies of <em>SMN2</em>.\xa0</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that if the proposed funding criteria for risdiplam limits the number of <em>SMN2</em> copies to 3 as per the current nusinersen funding criteria, then some individuals with Type 3 SMA may be missed at the time of screening. Members considered that the proposed funding criteria increased the limit number of <em>SMN2</em> copies to 4, then some individuals would be treated pre-symptomatically – who otherwise would manifest SMA type IIIb or IV (who would not otherwise be eligible for treatment), or may never become symptomatic.</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that based on previous consideration by PTAC and the Rare Disorders and Neurological Subcommittees, a large proportion of people with SMA would be assumed to have an SMA type IV phenotype if treated in the pre-symptomatic setting. The Committees considered it important that the morbidity associated with an SMA type IV phenotype be reflected in economic modelling in the decades after symptom onset with this phenotype, given the recommended assumption of lifelong benefit.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees discussed the impact of funding risdiplam for the treatment of pre-symptomatic SMA on Māori health areas of focus and Māori health outcomes. The Committees noted the lower reported prevalence and incidence of SMA in Māori, and considered the presence of a mutation in the <em>SMN1 </em>gene does not appear to be associated with or influenced by ethnicity. The Committees noted that SMA is not included as a Māori health area of focus in Te Whaioranga, Pharmac Māori responsiveness strategy.</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that routine screen of all newborns for SMA is not currently routinely available in New Zealand; however, that following the funding of nusinersen, this may be developed. The Committees noted that access to and utilisation of screening would not be changed with the addition of risdiplam as a treatment option in the pre-symptomatic setting.</p><h3><em style=""font-size: 14px;"">Health Benefit</em></h3><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that Medsafe has approved the use of risdiplam in people aged two months and over and that further assessment is currently underway to extend the indication to remove the age restriction. The Committees noted that all infants included in the RAINBOWFISH study were under two months old, and that the youngest started treatment at 28.5 days old.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted the 12-month interim results of the RAINBOWFISH trial, an open label study of infants with genetically diagnosed and pre-symptomatic SMA (<a href=""https://medically.gene.com/global/en/unrestricted/neuroscience/CURE-SMA-2022/curesma-2022-presentation-richard-rainbowfish-prelimina.html"" target=""_blank"">Finkel et al. Cure SMA 2022 presentation on behalf of the RAINBOWFISH study group, sponsored by Roche. Anaheim, USA; 2022 June 16).\xa0</a></p><p class=""ql-indent-1"">1.15.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that at the cut-off for interim data, seven infants had been treated with risdiplam for 12 months or more. Four infants had two <em>SMN2</em> copies, and three had &gt;2 <em>SMN2</em> copies (number of copies not further defined). The Committees noted the mean HINE-2 score change from baseline was 18.75. All infants were sitting without support, six patients achieved the highest levels of rolling (supine to prone), and five infants were walking independently. All included infants maintained the ability to swallow and were able to feed exclusively by mouth.</p><p class=""ql-indent-1"">1.15.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted the investigator’s report concluded that adverse events (AEs) were more reflective of the age of the infants rather than the underlying SMA, or treatment with risdiplam. The Committees noted that at 12 months no deaths, no serious AEs, or AEs that led to treatment withdrawal or discontinuation were reported. Members noted that unlike nusinersen, which is administered as an intrathecal injection, risdiplam does not carry the risks associated with intrathecal injection and sedation.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that there are currently no direct head-to-head trials of nusinersen and risdiplam in the pre-symptomatic setting. The Committees considered that while patient numbers in trials for each medicine are relatively small, which makes them difficult to compare, it is currently considered that both risdiplam and nusinersen have similar clinical effects on SMA. Members considered, that based on the similar mechanisms of action, this was biologically plausible.</p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that once new-born screening for SMA was in place, most individuals would be diagnosed and begin treatment pre-symptomatically. Members considered that this would provide additional treatment benefit in comparison to treatment initiation after the onset of symptoms.</p><h3><em style=""font-size: 14px;"">Suitability</em></h3><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees noted that risdiplam is a once daily oral medication, presented as a powder for reconstitution with purified or sterile water which is to be reconstituted by a healthcare professional. The Committees noted that risdiplam can also be given via nasogastric tube, or gastrostomy.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that not being required to travel to hospital for intrathecal treatment (as with nusinersen) was a clear suitability benefit for risdiplam, particularly for individuals who live in rural areas and may find accessing clinical centres for nusinersen treatment difficult.</p><h3><em style=""font-size: 14px;"">Cost and savings</em></h3><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that eventually 90% of those with pre-symptomatic SMA would initiate treatment with risdiplam preferentially to treatment with nusinersen, due to the suitability of oral treatment compared with repeated intrathecal injections. The Committees noted that this was supported by a recent discrete choice experiment conducted with patients and caregivers of patients with SMA <a href=""https://ojrd.biomedcentral.com/articles/10.1186/s13023-020-01667-3"" target=""_blank"">(Monnette et al. Orphanet J Rare Dis. 2021;16:36</a>).</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that there would be a cost associated with implementing a national screening service for SMA, but that this cost would be incurred regardless of the funding of risdiplam, as nusinersen has been funded for this indication already.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committees considered that, compared with nusinersen intrathecal injection treatment for SMA, oral risdiplam has the potential to reduce health system costs to a greater extent, with the same or similar efficacy likely to be achieved.</p><h3><em style=""font-size: 14px;"">Summary for assessment</em></h3><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Advisory Committees considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) </span>information<span style=""color: black;""> for risdiplam if it were to be funded in New Zealand for </span>pre-symptomatic treatment of SMA<span style=""color: black;"">. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committees’ assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span><span style=""color: black;"">The Committees noted that the PICO table below was relevant for all individuals with SMA not just those who will be diagnosed pre-symptomatically. The Committees also noted that the intervention would commence when individuals were less than 2 months old.\xa0</span></p><p><span style=""color: black;""><span class=""ql-cursor"">\ufeff</span></span><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000000R9aR&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ0000005Q0H"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000001LdUAYA0'}, 'change': None}]",Dec 2022,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aK2AS'}, 'Id': 'a0POZ000000R9aK2AS', 'Event_Date__c': '2022-08-12', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000EDjXQAW'}, 'change': None}]",Aug 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aM2AS'}, 'Id': 'a0POZ000000R9aM2AS', 'Event_Date__c': '2022-12-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000EDjcQAG'}, 'change': None}]",Dec 2022,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-01-19-proposal-to-fund-risdiplam-evrysdi-for-spinal-muscular-atrophy/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-01-19-proposal-to-fund-risdiplam-evrysdi-for-spinal-muscular-atrophy/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jan 2023', 'fs': 'Jan 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aN2AS'}, 'Id': 'a0POZ000000R9aN2AS', 'Event_Date__c': '2023-01-19', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-01-19-proposal-to-fund-risdiplam-evrysdi-for-spinal-muscular-atrophy/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Jan 2023', 'Status_History__c': 'a132P000000EDgeQAG'}, 'change': None}]",Jan 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2023', 'fs': 'Feb 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aO2AS'}, 'Id': 'a0POZ000000R9aO2AS', 'Event_Date__c': '2023-02-25', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Feb 2023', 'Status_History__c': 'a132P000000EDgjQAG'}, 'change': None}]",Feb 2023,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p>We sought clinical advice in March 2023 which informed this decision. The record of this advice will be available in the coming months</p>', 'fs': '<p>We sought clinical advice in March 2023 which informed this decision. The record of this advice will be available in the coming months</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2023-04-11-risdiplam/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2023-04-11-risdiplam/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2023', 'fs': 'Apr 2023', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ000000R9aQ2AS'}, 'Id': 'a0POZ000000R9aQ2AS', 'Event_Date__c': '2023-04-11', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2023-04-11-risdiplam/"" target=""_blank"">Notification letter</a></p>', 'Summary__c': '<p>We sought clinical advice in March 2023 which informed this decision. The record of this advice will be available in the coming months</p>', 'Formatted_Date__c': 'Apr 2023', 'Status_History__c': 'a132P000000EDhHQAW'}, 'change': None}]",Apr 2023,False,True
